Ceryvyn Therapeutics Limited (CKDXF)
OTC Markets OTCPK · USD · Healthcare · Biotechnology
$0.0107 (+0.00%) as of
Key statistics
- Market cap
- 14.64M
- P/E (TTM)
- 0.06
- EPS (TTM)
- 0.1700
- Dividend yield
- 0.00%
- 52-week range
- 0.0100 – 0.4400
- Beta
- 1.48
- Revenue (TTM)
- 1k
- Profit margin
- 33,044,500.00%
- Volume
- 130.00
About Ceryvyn Therapeutics Limited
Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Hawthorn East, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.